BioSpace News Archive

Lexogen GmbH, a Vienna-based market leader in Next-Generation Sequencing (NGS) and transcriptomics announced today the launch of a pioneering ultra-high-throughput SARS-CoV-2 test that will allow for the first time a true mass screening of the whole population.

Selva Therapeutics, Inc. announced today that the company has received U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. Selva also announced preclinical data demonstrating in several host cell

AngioDynamics, Inc., a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced the safety and efficacy results from the Registry of AngioVac* System Procedures In Detail database.

The American Academy of Pediatrics has selected ArborMetrix as its partner to develop and grow a clinical registry to advance the health, well-being, and development of all children.

ABEC , a global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced Qilu Pharmaceutical Co. has again selected ABEC to rapidly expand production capacity at their cGMP manufacturing facility in Jinan, Shandong, China. ABEC is delivering several sets of large-scale

Nortech Systems Incorporated (Nasdaq: NSYS) (the “Company”), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical, aerospace & defense and industrial markets, reported net sales of $26.3 million for the third quarter ended September 30, 2020, compared with $30.1 million for the third quarter of 2019. Operating income for the th

The integration of Grifols PharmacyKeeper and clinical education resources from TRC Healthcare will help pharmacy leaders by delivering the most current and relevant evidence-based education available

Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the presentation of preclinical data of its lead investigational therapies: XTX201, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4 antibody

KARL STORZ Imaging of Goleta, California, celebrates its 30th anniversary on November 12, 2020.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced financial results and a corporate update for the quarter ended September 30, 2020.